California Public Employees Retirement System raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 181,900 shares of the company’s stock after acquiring an additional 2,600 shares during the quarter. California Public Employees Retirement System owned 0.21% of Neurocrine Biosciences worth $11,147,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its stake in shares of Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after buying an additional 193 shares during the last quarter. Comerica Bank acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth $210,000. Trexquant Investment LP acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth $246,000. World Asset Management Inc acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth $246,000. Finally, Stifel Financial Corp acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth $246,000.
Neurocrine Biosciences, Inc. (NBIX) opened at $79.00 on Friday. Neurocrine Biosciences, Inc. has a one year low of $38.43 and a one year high of $83.84. The firm has a market cap of $6,990.00, a PE ratio of -35.59 and a beta of 0.35. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter last year, the firm earned ($0.43) EPS. equities analysts expect that Neurocrine Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.
In other Neurocrine Biosciences news, insider Kyle Gano sold 24,818 shares of Neurocrine Biosciences stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the sale, the insider now owns 84,596 shares in the company, valued at approximately $6,010,545.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary A. Lyons sold 10,000 shares of Neurocrine Biosciences stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $72.92, for a total value of $729,200.00. Following the completion of the sale, the director now owns 272,066 shares of the company’s stock, valued at approximately $19,839,052.72. The disclosure for this sale can be found here. Insiders sold a total of 116,405 shares of company stock valued at $8,588,519 in the last 90 days. 4.80% of the stock is owned by company insiders.
Several research analysts have recently issued reports on NBIX shares. Robert W. Baird reaffirmed an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Oppenheimer set a $85.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Jefferies Group reaffirmed a “buy” rating and set a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 price target (up previously from $72.00) on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Finally, BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. Neurocrine Biosciences currently has an average rating of “Buy” and an average target price of $81.13.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/12/neurocrine-biosciences-inc-nbix-position-increased-by-california-public-employees-retirement-system.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.